Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Ovulation Induction”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,009 records · Page 56Linked to original sources
PubMed1989

[Pre-decision algorithms for the induction of ovulation in fertilization in vitro].

The success of medically assisted procreation techniques depends on the influence of numerous parameters and, especially the quality of ovarian hyperstimulation. The need of a homogeneous treatment within the medical team has led us to elaborate a system of assistance in decision making in terms of stimulation of ovulation. A first system was developed for a classical stimulation protocol, type clomiphene-gonadotropin. The limited number of decision making parameters (six) as well as the limited number of therapeutic decisions (six) has enabled us to developed a particularly performing algorithm system.

Algorithms↗
PubMedDate not supplied

Initial experiences with subcutaneous pulsatile human menopausal gonadotropin administration: successful induction of ovulation in patients with polycystic ovarian disease.

Human menopausal gonadotropin (hMG) was administered to 10 patients with polycystic ovarian disease (PCOD) who had failed to ovulate in response to clomiphene citrate. Five patients (group 1) were treated with intramuscular hMG injections daily, on an individually adjusted regimen. Five others (group 2) were stimulated with subcutaneous hMG in a pulsatile fashion by means of a portable infusion minipump. The pulse doses ranged between 3.5 and 7.7 IU FSH per pulse at a constant frequency of 90 minutes. Sixteen of 18 treatment cycles were ovulatory, 9 under intramuscular, and 7 under subcutaneous treatment. A total of two patients conceived with singleton pregnancies, one in each treatment group. Neither ovarian hyperstimulation nor complications of injections were noted. The amount of subcutaneous hMG required to achieve ovulation was significantly less (46.5%; P less than .001) than that needed with intramuscular administration. However, there were no differences in the duration of stimulation periods, the lengths of luteal phases, or serum E2 and gonadotropin levels between the groups. In conclusion, pulsatile subcutaneous hMG administration may be an alternative delivery mode for patients with PCOD.

Adult↗
PubMed1985

[Monitoring the induction of ovulation by HMG-hCG].

Despite correct management of HMG and hCG, the margin between effective dose and overdose is narrow. Surveillance must be clinical, biochemical and echographic. Biochemistry and echography give information on follicle maturation. Echography is a particularly valuable means of monitoring the effect of administration of hypophyseal hormones on the development of follicles.

Chorionic Gonadotropin↗
PubMed1987

Induction of ovulation in anoestrous mares with a slow-release implant of a GnRH analogue (ICI 118 630).

A total of 18 experimental pony and 136 commercial maiden, barren and foaling Thoroughbred mares in seasonal or lactation-related anoestrus were injected subcutaneously with 1 or 2 slow-release D,L-lactide-glycolide co-polymer implants impregnated with 0.9 or 1.8 mg of the potent GnRH analogue, ICI 118 630, to give a daily release of, respectively, 30 or 60 micrograms analogue for 28 days; 32 of the Thoroughbred mares were also given a daily oral dose of 27.5 mg allyl trenbolone for 5 days after injection of the implant. Thirteen pony (76%) and 120 Thoroughbred (88%) mares ovulated 3-18 days after treatment with ICI 118 630 and the additional treatment with allyl trenbolone did not significantly reduce the considerable variation in the interval between treatment with GnRH analogue and ovulation. Of 100 Thoroughbred mares mated during the GnRH analogue-induced oestrus, (70%) conceived. The results of this trial demonstrated that low-dose, slow-release formulations of GnRH agonists have considerable potential as a practical method of hastening renewed ovarian cyclicity in anoestrous mares.

Anestrus↗